ArticleChinese journal of cancer research = Chung-kuo yen cheng yen chiu2021

Vorolanib, an oral VEGFR/PDGFR dual tyrosine kinase inhibitor for treatment of patients with advanced solid tumors: An open-label, phase I dose escalation and dose expansion trial.

Yan Song et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.